Conclusions: Eravacycline was very active against Gram-positive clinical isolates, including MDR strains, with the highest MIC of eravacycline at 1 µg/ml. MIC90 ranged from 0.015 - 1 µg/ml. Overall, eravacycline showed promising activity against all strains tested including MDR isolates.

All strains tested were susceptible to eravacycline. All strains with very high eravacycline MIC at 1 µg/ml were shown to have promising activity against all strains tested including MDR isolates.

Data from the recently completed Phase 3 trials will be used in determining the clinical breakpoints.

Eravacycline exhibited excellent activity against many isolates, and we show promise for the treatment of infections caused by Gram-positive bacteria, including MDR isolates.

References
5. https://www.accessdata.fda.gov/drugsatfda_doc/...